Celularity Inc
CELU3.120USD
0.000
交易中 （美東）報價延遲15分鐘
70.35M總市值
虧損本益比TTM
關於 Celularity Inc 公司
Celularity Inc. 是一家再生和細胞醫學公司。該公司正在開發和商業化先進的生物材料產品和同種異體、冷凍保存、胎盤衍生細胞療法，這些療法均源自產後胎盤。該公司的治療計劃針對衰老相關疾病，包括退行性疾病、癌症和免疫疾病，使用間充質樣粘附基質細胞、用 CAR 改造的 T 細胞（CAR T 細胞）以及轉基因和未轉基因的自然殺傷 (NK) 細胞。該公司開發、製造和商業化源自產後胎盤組織（包括臍帶）結構組織成分的先進生物材料產品。其先進的生物材料包括 Celularity 肌腱包裹物、FUSE 骨空隙填充物和 Celularity 胎盤基質。其先進的生物材料產品包括 Biovance、Interfyl 和 Rebound 產品。其平臺是Celularity IMPACT（免疫調節胎盤衍生同種異體細胞療法）。
公司簡介
公司代碼CELU
公司名稱Celularity Inc
上市日期May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
員工數量123
證券類型Ordinary Share
年結日May 23
公司地址170 Park Ave
城市FLORHAM PARK
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編07932
電話19087682170
網址https://celularity.com/
公司代碼CELU
上市日期May 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
持股股東
持股股東
佔比
Genting Bhd
26.45%
Hariri (Robert J)
11.92%
Starr International Company, Inc.
6.38%
Celgene Corporation
4.99%
Lung Biotechnology Inc
3.33%
Other
46.93%
股東類型
持股股東
佔比
Corporation
36.88%
Individual Investor
14.45%
Investment Advisor
9.43%
Insurance Company
3.19%
Investment Advisor/Hedge Fund
1.17%
Hedge Fund
0.35%
Research Firm
0.30%
Bank and Trust
0.20%
Venture Capital
0.04%
Other
33.99%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
104
15.81M
66.01%
-1.35M
2025Q1
140
16.18M
70.80%
+52.81K
2024Q4
156
14.05M
63.43%
-1.62M
2024Q3
169
14.41M
66.16%
-2.07M
2024Q2
181
15.12M
69.86%
-663.91K
2024Q1
187
14.36M
66.56%
-1.48M
2023Q4
186
12.31M
65.02%
-347.56K
2023Q3
186
12.52M
68.51%
+23.28K
2023Q2
200
12.33M
70.15%
-1.64M
2023Q1
224
13.36M
90.76%
-717.66K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Genting Bhd
6.34M
26.45%
--
--
May 15, 2025
Hariri (Robert J)
2.85M
11.92%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
6.38%
--
--
May 15, 2025
Celgene Corporation
1.20M
4.99%
--
--
Feb 07, 2025
Lung Biotechnology Inc
796.88K
3.33%
--
--
Dec 31, 2023
C.V. Starr & Co., Inc.
764.07K
3.19%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
500.13K
2.09%
--
--
Mar 31, 2025
Kehler (Dean C)
281.94K
1.18%
--
--
Feb 07, 2025
Geode Capital Management, L.L.C.
136.04K
0.57%
+4.53K
+3.45%
Mar 31, 2025
Diamandis (Peter)
134.31K
0.56%
-63.82K
-32.21%
May 15, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
公告日期
類型
比率
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
Feb 23, 2024
Merger
10<1
